Durham Startup Has Developed New Cancer Therapy
Incyclix Bio is currently testing a targeted treatment for breast and ovarian cancers across 19 hospitals.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Do you believe new targeted cancer therapies effectively reduce treatment side effects for patients?
The Durham-based biotech startup Incyclix Bio has secured $52 million to advance its clinical trials for INX 315. The new cancer therapy is designed to overcome drug resistance in patients with breast or ovarian cancer.
Why it matters
Many existing cancer treatments lose their efficacy over time as cells develop resistance to traditional CDK4/6 inhibitors. By targeting CDK2, this new therapy aims to maintain effectiveness while reducing the severe side effects associated with high-dose chemotherapy.
Incyclix Bio is currently conducting clinical trials at 19 hospitals with a cohort of 60 patients. The study follows the FDA Project Optimus initiative to identify the lowest effective dosage.
The players
Incyclix Bio
A Durham-based biotechnology startup focused on developing targeted therapies for cancer treatment.
Patrick Roberts
The founder of Incyclix Bio who established the company in 2020.
G1 Therapeutics
A biotech firm that was acquired by Pharmacosmos for $405 million in 2024.
Pharmacosmos
A pharmaceutical company that completed the acquisition of G1 Therapeutics in 2024.
The details
INX 315 uses a specialized approach to target CDK2 inhibitors, which allows the treatment to override resistance mechanisms that often hinder conventional therapies. The company is actively working to minimize patient bodily harm by refining dosage protocols.
Timeline
Incyclix Bio was founded in 2020.
Pharmacosmos acquired G1 Therapeutics for $405 million in 2024.
Early clinical findings are expected in December 2026.
A new funding round is planned for early 2027.
Deeper Dive
The development of INX 315 follows the framework set by the FDA Project Optimus initiative. This research strategy prioritizes finding the lowest effective dose for cancer therapies to improve long-term patient outcomes.
This development offers potential new treatment pathways for patients who have seen their breast or ovarian cancer become resistant to standard CDK4/6 inhibitors. By focusing on minimizing side effects, the research may eventually lead to therapies that offer better quality of life during treatment.
The takeaway
Targeted therapies like INX 315 represent a shift toward precision medicine that seeks to bypass resistance mechanisms in cancer cells. Patients should consult with their oncologists to stay informed about clinical trial eligibility and evolving treatment options.
What happens next
Incyclix Bio will present early clinical findings for 60 patients at the San Antonio Breast Cancer Symposium in December 2026. The company also plans to initiate a new funding raise in early 2027.
Further reading
For more information on ongoing research, visit the Cancer section.
Source note: This article includes information reported by Technical.
Live Poll
Do you believe new targeted cancer therapies effectively reduce treatment side effects for patients?
